|
gptkbp:instanceOf
|
hypolipidemic agent
fibrate
|
|
gptkbp:ATCCode
|
C10AB08
|
|
gptkbp:CASNumber
|
52214-84-3
|
|
gptkbp:category
|
gptkb:carboxylic_acid
organochloride
lipid-lowering agent
|
|
gptkbp:chemicalFormula
|
C13H14Cl2O3
|
|
gptkbp:chemspider_id
|
2664
|
|
gptkbp:contraindication
|
severe kidney disease
severe liver disease
gallbladder disease
|
|
gptkbp:discoveredBy
|
gptkb:Sanofi
|
|
gptkbp:drugbank_id
|
DB08907
|
|
gptkbp:eliminationHalfLife
|
35 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ciprofibrate
|
|
gptkbp:introducedIn
|
1982
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PPARĪ± agonist
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
289.16 g/mol
|
|
gptkbp:pubchem_cid
|
2766
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
muscle pain
liver enzyme abnormalities
gastrointestinal disturbances
|
|
gptkbp:synonym
|
2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoic acid
|
|
gptkbp:UNII
|
8KQ660G10Z
|
|
gptkbp:usedFor
|
treatment of hyperlipidemia
|
|
gptkbp:bfsParent
|
gptkb:fibrates
|
|
gptkbp:bfsLayer
|
8
|